Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
News|Articles|August 5, 2024
Roundup: Novel Drug Approvals in 2024
In the first half of 2024, the FDA approved 23 novel drugs for conditions including alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more.
Advertisement
Advertisement
In the first half of 2024, the FDA has approved 23 novel drugs, including indications for alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more. In the first 6 months alone, there were 20 novel approvals.
Related to this article
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
Advertisement
Advertisement